VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ISRGIntuitive Surgical, Inc.
$404.27$143.6B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksISRGFinancials

Intuitive Surgical, Inc. (ISRG) Financials

27Y historyFree accessUpdated daily

Operating margins expanded to 30.9% in 2026Q1, reflecting efficient scaling as revenue growth reached 23.0% year-over-year.

ISRG Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99
Sales/Revenue10.58B10.06B8.35B7.12B6.22B5.71B4.36B4.48B3.72B3.13B2.7B2.38B2.13B2.27B2.18B1.76B1.41B1.05B874.92M600.83M372.68M227.34M138.8M91.67M72.02M51.67M26.62M10.19M
Revenue Growth %21.43%20.51%17.24%14.49%8.97%31.01%-2.68%20.25%19.03%15.7%13.42%11.85%-5.89%3.96%23.99%24.37%34.29%20.26%45.62%61.22%63.93%63.78%51.41%27.29%39.38%94.08%161.22%-
Cost of Goods Sold3.57B3.42B2.72B2.39B2.03B1.75B1.5B1.37B1.12B934.8M814.3M806.5M717.9M670.9M608.5M483.5M383M301.12M254.14M186.54M124.85M73.77M50.81M47.65M34.58M28.22M13.28M7.03M
COGS % of Revenue-34%32.54%33.61%32.56%30.68%34.35%30.55%30.08%29.88%30.11%33.82%33.68%29.62%27.93%27.51%27.11%28.62%29.05%31.05%33.5%32.45%36.61%51.97%48.02%54.61%49.88%68.98%
Gross Profit7.02B6.64B5.63B4.73B4.2B3.96B2.86B3.11B2.6B2.19B1.89B1.58B1.41B1.59B1.57B1.27B1.03B751.05M620.78M414.29M247.84M153.57M87.99M44.03M37.44M23.45M13.35M3.16M
Gross Margin %66.29%66%67.46%66.39%67.44%69.32%65.65%69.45%69.92%70.12%69.89%66.18%66.32%70.38%72.07%72.49%72.89%71.38%70.95%68.95%66.5%67.55%63.39%48.03%51.98%45.39%50.12%31.02%
Gross Profit Growth %-17.89%19.13%12.71%6%38.35%-8.01%19.43%18.69%16.08%19.79%11.61%-11.32%1.52%23.28%23.67%37.14%20.99%49.84%67.16%61.38%74.53%99.85%17.61%59.62%75.76%322.04%-
Operating Expenses3.79B3.7B3.29B2.96B2.62B2.14B1.81B1.74B1.4B1.14B944.9M837.9M869M741.7M692.2M579M474.8M373.61M309.94M207.54M140.48M84.8M66.81M55.91M57.66M43.84M35.62M22.71M
OpEx % of Revenue-36.73%39.34%41.59%42.09%37.43%41.56%38.76%37.72%36.42%34.94%35.14%40.77%32.74%31.77%32.95%33.6%35.51%35.43%34.54%37.69%37.3%48.13%60.99%80.05%84.84%133.8%222.83%
Selling, General & Admin2.43B2.38B2.14B1.96B1.74B1.47B1.22B1.18B986.6M810.9M705.3M640.5M691M574M522.2M438.8M358.8M278.51M230.57M158.69M110.7M67.44M48.99M39.72M40.86M29.99M19.14M9.34M
SG&A % of Revenue-23.7%25.62%27.57%27.96%25.68%27.91%26.31%26.49%25.92%26.08%26.86%32.42%25.34%23.97%24.97%25.39%26.47%26.35%26.41%29.7%29.67%35.3%43.33%56.74%58.03%71.88%91.62%
Research & Development1.36B1.31B1.15B998.8M879M671M595.1M557.3M418.1M328.6M239.6M197.4M178M167.7M170M140.2M116M95.1M79.37M48.86M29.78M17.35M17.81M16.19M16.79M13.85M11.73M11.13M
R&D % of Revenue-13.03%13.71%14.02%14.13%11.75%13.65%12.44%11.23%10.5%8.86%8.28%8.35%7.4%7.8%7.98%8.21%9.04%9.07%8.13%7.99%7.63%12.83%17.66%23.32%26.81%44.07%109.2%
Other Operating Expenses000000000000000000000000004.75M11.58M
Operating Income3.22B2.95B2.35B1.77B1.58B1.82B1.05B1.37B1.2B1.05B945.2M740M544.8M852.5M878.1M694.8M555.2M377.44M310.83M206.74M107.36M68.77M21.18M-11.88M-20.22M-20.38M-22.28M-19.55M
Operating Margin %30.45%29.27%28.12%24.8%25.35%31.89%24.09%30.69%32.21%33.71%34.95%31.04%25.56%37.64%40.3%39.54%39.29%35.87%35.53%34.41%28.81%30.25%15.26%-12.96%-28.07%-39.45%-83.67%-191.81%
Operating Income Growth %-25.4%32.95%12.03%-13.39%73.46%-23.62%14.6%13.73%11.57%27.73%35.83%-36.09%-2.92%26.38%25.14%47.1%21.43%50.35%92.58%56.1%224.64%278.32%41.24%0.8%8.5%-13.95%-
EBITDA3.76B3.62B2.81B2.17B1.94B2.14B1.33B1.57B1.32B1.15B1.03B829.5M619.2M919.8M935.9M741.3M595.6M412.02M335.92M219.77M142.62M75.5M28.3M-1.25M-15.67M-15.67M-17.52M-17.31M
EBITDA Margin %35.52%35.99%33.66%30.45%31.23%37.44%30.57%35.15%35.43%36.74%38.24%34.79%29.05%40.61%42.95%42.18%42.15%39.16%38.39%36.58%38.27%33.21%20.39%-1.36%-21.76%-30.33%-65.82%-169.8%
EBITDA Growth %27.37%28.88%29.59%11.64%-9.13%60.47%-15.37%19.3%14.78%11.17%24.67%33.96%-32.68%-1.72%26.25%24.46%44.56%22.65%52.85%54.09%88.91%166.83%2361.79%92.02%0.01%10.58%-1.27%-
D&A (Non-Cash Add-back)536.2M677.1M462M402.2M365.8M317M282.5M199.7M120.1M95M88.9M89.5M74.4M67.3M57.8M46.5M40.4M34.58M25.08M13.03M35.27M6.73M7.11M10.63M4.55M4.71M4.75M2.24M
EBIT3.22B2.95B2.35B1.77B1.58B1.82B1.05B1.37B1.2B1.06B949.7M740M544.8M852.5M878.1M694.8M555.2M377.4M310.83M206.74M107.36M68.77M21.18M-11.88M-20.22M-20.38M-22.28M-19.55M
Net Interest Income360.6M365.9M324.9M192.1M29.7M69.3M157.2M127.7M80.1M41.9M35.6M18.5M13.9M18.4M15.8M14.9M16.6M18.7M0000000000
Interest Income360.6M365.9M324.9M192.1M29.7M69.3M157.2M127.7M80.1M41.9M35.6M18.5M13.9M18.4M014.9M16.6M18.67M0000000000
Interest Expense0000000000000015.8M0000000000000
Other Income/Expense360.6M365.9M324.9M192.1M29.7M69.3M157.2M127.7M80.1M41.9M35.6M18.5M4.2M18.4M15.8M14.9M17.1M18.67M24.37M30.49M12.78M5.04M3.02M2.26M1.8M42K-108K0
Pretax Income3.58B3.31B2.67B1.96B1.61B1.89B1.21B1.5B1.28B1.1B980.8M758.5M549M870.9M893.9M709.7M572.3M396.11M335.2M237.23M120.14M73.81M24.2M-9.62M-18.42M-20.34M-22.39M0
Pretax Margin %33.86%32.9%32.01%27.5%25.82%33.1%27.69%33.54%34.36%35.04%36.27%31.81%25.75%38.45%41.03%40.39%40.5%37.65%38.31%39.48%32.24%32.47%17.44%-10.5%-25.58%-39.36%-84.08%-
Income Tax584.4M434.8M336.3M141.6M262.4M162.2M140.2M120.4M154.5M436.5M244.9M169.7M130.2M199.9M237.3M214.6M190.5M163.5M130.89M92.7M48.09M-20.33M726K00-3.68M-3.75M-1.13M
Effective Tax Rate %16.31%13.13%12.58%7.23%16.33%8.58%11.62%8.01%12.08%39.81%24.97%22.37%23.72%22.95%26.55%30.24%33.29%41.28%39.05%39.07%40.03%-27.54%3%0%0%18.11%16.77%-
Net Income2.98B2.86B2.32B1.8B1.32B1.7B1.06B1.38B1.13B660M735.9M588.8M418.8M671M656.6M495.1M381.8M232.61M204.31M144.54M72.04M94.13M23.48M-9.62M-18.42M-16.7M-18.52M-18.41M
Net Margin %28.15%28.38%27.81%25.24%21.25%29.85%24.33%30.8%30.29%21.09%27.21%24.69%19.65%29.62%30.14%28.17%27.02%22.11%23.35%24.06%19.33%41.41%16.91%-10.5%-25.58%-32.32%-69.57%-180.68%
Net Income Growth %20.31%22.97%29.18%35.98%-22.43%60.72%-23.11%22.29%70.89%-10.31%24.98%40.59%-37.59%2.19%32.62%29.68%64.14%13.85%41.36%100.62%-23.47%300.95%343.98%47.76%-10.31%9.84%-0.59%-
Net Income (Continuing)3B2.88B2.34B1.82B1.34B1.73B1.07B1.38B1.13B670.9M735.9M588.8M418.8M671M656.6M495.1M381.8M232.61M204.31M144.54M72.04M94.13M23.48M-9.62M-18.42M-16.7M-18.52M-18.41M
Discontinued Operations0000000000000000000000000000
Minority Interest122.7M117.7M95.9M89.7M70.7M50.4M27.6M20.9M8.7M1.6M000000000000000000
EPS (Diluted)8.287.876.425.033.654.662.943.853.161.892.081.731.231.861.781.371.050.660.570.410.210.280.07-0.05-0.11-0.10-0.17-0.85
EPS Growth %20.97%22.59%27.63%37.81%-21.67%58.5%-23.64%21.84%67.2%-9.13%20.23%40.65%-33.87%4.49%29.93%30.48%59.09%15.79%39.02%95.24%-25%276.34%264.24%58.82%-10%41.18%80%-
EPS (Basic)-8.006.545.123.724.793.023.983.311.972.131.761.261.861.831.401.080.670.580.420.220.300.08-0.05-0.11-0.10-0.17-0.85
Diluted Shares Outstanding359.8M362.7M362M357.4M362M365.8M360.9M358.5M356.4M348.9M353.7M341.1M339.3M360.97M369.9M361.8M362.7M352.85M359.49M351.19M342.84M337.39M314.78M212.63M164.06M161.17M107.08M21.77M
Basic Shares Outstanding354.9M356.9M355.2M351.2M355.7M356.1M351M346.2M341.1M335.1M344.7M333.9M332.1M360.97M358.2M352.8M352.8M344.68M349.89M340.48M330.63M315.63M303.24M212.63M164.06M161.17M107.08M21.77M
Dividend Payout Ratio----------------------------

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrong
Balance SheetFortress
Cash FlowRobust
Top Statement Risk

Procedure volume saturation risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Sustained Revenue Growth Momentum

As reported in recent financial statements, ISRG achieved a 23.0% year-over-year revenue growth in 2026Q1, signaling that the company's recurring revenue model continues to successfully capture increased procedure volumes despite the potential headwinds posed by the broader adoption of GLP-1 weight-loss medications in the surgical market.

The acceleration in top-line growth suggests that the installed base of robotic systems is being utilized with higher intensity, driving consistent demand for high-margin consumables. Investors should monitor whether this growth trajectory remains durable as the company transitions its installed base to the newer da Vinci 5 platform.

Resilient Gross Margin Profile

Based on the company's reported figures, ISRG has maintained a robust gross margin of approximately 66.1% as of 2026Q1, demonstrating significant pricing power and a structural advantage in its proprietary instrument ecosystem that effectively insulates the firm from the commodity-like pricing pressures seen in traditional medical device manufacturing.

This margin stability is particularly impressive given the ongoing R&D investments and the potential for initial manufacturing inefficiencies associated with new system rollouts. The ability to sustain these levels suggests that the razor-blade business model remains highly effective at extracting value from the existing installed base.

Operating Leverage Scaling Efficiency

According to the provided income statement data, ISRG's operating margin expanded to 30.9% in 2026Q1, indicating that the company is successfully scaling its operating expenses slower than its gross profit, thereby demonstrating strong operational leverage as the business continues to expand its global footprint and clinical indications.

The disciplined management of SG&A relative to revenue growth suggests that the company is benefiting from economies of scale in its sales and training infrastructure. This trend warrants further investigation to determine if future margin expansion can be sustained as the company increases its marketing spend for new platforms.

Stock-Based Compensation Impact Analysis

As indicated by the quarterly filings, stock-based compensation has risen to $209.5 million in 2026Q1, representing a non-trivial portion of operating expenses that investors should scrutinize to ensure that reported EPS growth is not being overly inflated by the dilution of existing shareholders through aggressive equity-based incentive programs.

While the company maintains strong net income margins, the persistent increase in SBC expenses suggests that the true economic cost of talent retention is rising. Analysts should adjust for these non-cash charges to better understand the underlying cash-generative capacity of the core surgical robotics business.

Risks to Sustained Margin Expansion

Based on the provided data, a potential short-term risk exists as the company's operating margin has fluctuated between 23% and 31% over the last ten quarters, suggesting that the transition to new hardware cycles may introduce volatility that could temporarily compress profitability and challenge current market valuation multiples.

The reliance on high-margin recurring revenue makes the company sensitive to any systemic decline in procedure volumes, whether driven by macro-economic factors or shifts in clinical standards of care. Investors should remain cautious regarding the potential for margin dilution if the mix shifts toward lower-margin leasing arrangements.

ISRG — Frequently Asked Questions

Quick answers to the most common questions about buying ISRG stock.

What was Intuitive Surgical, Inc.'s (ISRG) revenue in 2025?

For fiscal year 2025, Intuitive Surgical, Inc. (ISRG) reported total revenue of $10.06B. This represents a 98651.0% increase compared to $10.2M in 1999.

Is Intuitive Surgical, Inc. (ISRG) profitable?

Intuitive Surgical, Inc. (ISRG) is profitable, generating $2.86B in net income for the fiscal year ending 2025 with a net profit margin of 28.4%.

What is Intuitive Surgical, Inc.'s operating profit margin?

Intuitive Surgical, Inc. (ISRG) reported an operating income of $2.95B, resulting in an operating profit margin of 29.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Intuitive Surgical, Inc.'s gross profit and gross margin?

Intuitive Surgical, Inc. (ISRG) generated $6.64B in gross profit for the year, representing a gross profit margin of 66.0%. This demonstrates the company's core pricing power and production efficiency.